Yosemite Raises $350 Million as Reed Jobs Expands Cancer-Focused Investment Strategy

Yosemite, a San Francisco-based venture capital firm specialising in oncology investments, has closed its second fund with $350 million in capital.

The firm invests in biotechnology and healthcare innovations aimed at making cancer non-lethal through the development of new treatments and medical technologies.

Reed Jobs Founded Yosemite in 2015

Founded in 2015 by Reed Jobs, Yosemite focuses on supporting companies developing solutions in cancer research and treatment.

Suggested Readings (News continues below)

Ronaldo Retires From International Football Weeks After Portugal Camp Walkout and Manager Dispute

Newham Councillor Turns on Residents Over Fly-Tipping and Demands Pride in Local Streets

Angela Eagle Tells Brexit Critics to ‘Get a Life’ as EU Demands Billions and Criminal Deportation Ban

Harrods Accused of Delaying Al Fayed Abuse Survivors’ Compensation While Challenging Family Control of £118m Estate

The venture capital firm backs innovations across the biotechnology and healthcare sectors, with oncology remaining its primary investment focus.

Major Institutions and Investors Back the Firm

Yosemite’s historical limited partners include several prominent investors and institutions, among them John Doerr, Emerson Collective, Memorial Sloan Kettering Cancer Center, The Rockefeller University, the Massachusetts Institute of Technology (MIT) and Amgen.

Yosemite’s Investment Team

The firm’s team also includes Matt Bettonville and Dan McHugh.

Yosemite’s portfolio includes investments in companies operating across the biotechnology and healthcare industries, with further details available through its published investment listings.